Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders by Schaaf, Christian P. et al.
Oligogenic heterozygosity in individuals with
high-functioning autism spectrum disorders
Christian P. Schaaf1,{, Aniko Sabo2,{, Yasunari Sakai1,4, Jacy Crosby5, Donna Muzny2,
Alicia Hawes2, Lora Lewis2, Humeira Akbar2, Robin Varghese2, Eric Boerwinkle5,
Richard A. Gibbs1,2,∗ and Huda Y. Zoghbi1,3,4,6,∗
1Department of Molecular and Human Genetics,
2Human Genome Sequencing Center and
3Departments of
Pediatrics and Neuroscience, Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030,
USA,
4Howard Hughes Medical Institute, USA,
5Center for Human Genetics, University of Texas, Health Science
Center at Houston, Houston, TX 77030, USA and
6Jan and Dan Duncan Neurological Research Institute at Texas
Children’s Hospital, Houston, TX 77030, USA
Received March 15, 2011; Revised May 3, 2011; Accepted May 25, 2011
Autism spectrum disorders (ASDs) are a heterogeneous group of neuro-developmental disorders. While sig-
niﬁcant progress has been made in the identiﬁcation of genes and copy number variants associated with syn-
dromic autism, little is known to date about the etiology of idiopathic non-syndromic autism. Sanger
sequencing of 21 known autism susceptibility genes in 339 individuals with high-functioning, idiopathic
ASD revealed de novo mutations in at least one of these genes in 6 of 339 probands (1.8%). Additionally, mul-
tiple events of oligogenic heterozygosity were seen, affecting 23 of 339 probands (6.8%). Screening of a
control population for novel coding variants in CACNA1C, CDKL5, HOXA1, SHANK3, TSC1, TSC2 and
UBE3A by the same sequencing technology revealed that controls were carriers of oligogenic heterozygous
events at signiﬁcantly (P < 0.01) lower rate, suggesting oligogenic heterozygosity as a new potential
mechanism in the pathogenesis of ASDs.
INTRODUCTION
Autism spectrum disorders (ASDs) are a heterogeneous group of
neuro-developmental disorders that are characterized by
impaired social interaction and communication, and by restricted
and repetitive behaviors. The autistic disorder (AD), Asperger
syndrome (AS) and pervasive developmental disorder not other-
wise speciﬁed (PDD-NOS) are recognized as three subgroups of
the ASDs by the current version of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV). The estimated preva-
lence of the ASD is 1/91 among 3–17 years old and 1/110
among 8 years old children (1,2).
ASDs are highly heritable, as evidenced by twin and family
studies suggesting the heritability of autism to be .90%.
Autism affects predominantly males, with an overall
male-to-female ratio of 4:1. The male predominance is much
more pronounced in high-functioning autism and AS, and
may be as high as 14:1 within these subgroups (3). Recent
advances in the ﬁeld of autism genetics have led to the identi-
ﬁcation of several autism susceptibility genes and the appreci-
ation of both de novo and inherited copy number variants
(CNVs) in the etiology of ASDs (4,5).
In contrast to studies of CNV, genetic linkage and genome-
wide association studies have been slower to identify suscep-
tibility genes contributing to the heritability of autism, and
many association analyses have had inadequate power. It is
recognized that each genetic susceptibility locus identiﬁed to
date accounts for only a small fraction of ASD cases (typically
,1%). While signiﬁcant progress has been made in the identi-
ﬁcation of genes and CNVs associated with syndromic autism
(i.e. ASD as part of an underlying genetic syndrome as well as
ASD associated with congenital malformations and facial
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Advance Access published on May 30, 2011Table 1. Novel, coding non-synonymous variants detected by Sanger sequencing of 21 autism susceptibility genes in 339 probands with the ASD
Gene name Chr Coordinate Allele Mutation type RefSeqID Ref AA Var AA Number affected
patients
Number affected
controls
ARX chrX 24941366 T/G Missense NM_139058 Thr Pro 1 0
CACNA1C chr12 2437094 C/T Missense NM_000719 Arg Cys 1 0
CACNA1C chr12 2465684 T/C Missense NM_000719 Ile Thr 1 2
CACNA1C chr12 2484330 G/T Missense NM_000719 Gly Val 0 1
CACNA1C chr12 2529447 G/A Missense NM_000719 Gly Arg 1 0
CACNA1C chr12 2564900 G/A Missense NM_000719 Gly Arg 1 0
CACNA1C chr12 2564912 C/T Missense NM_000719 Pro Ser 4 4
CACNA1C chr12 2576670 T/G Missense NM_000719 Phe Cys 1 0
CACNA1C chr12 2590088 G/A Missense NM_000719 Val Ile 0 1
CACNA1C chr12 2656634 G/A Missense NM_000719 Ala Thr 1 0
CACNA1C chr12 2658877 G/A Missense NM_000719 Gly Ser 2 0
CACNA1C chr12 2658928 G/A Missense NM_000719 Ala Thr 1 0
CACNA1C chr12 2659126 G/A Missense NM_000719 Gly Ser 0 1
CACNA1C chr12 2659162 G/A Missense NM_000719 Gly Arg 2 0
CACNA1C chr12 2662090 T/C Missense NM_000719 Leu Pro 1 0
CACNA1C chr12 2665254 C/T Missense NM_000719 Arg Cys 6 0
CACNA1C chr12 2667958 G/C Missense NM_000719 Ala Pro 0 1
CACNA1C chr12 2668046 G/A Missense NM_000719 Ser Asn 0 1
CACNA1C chr12 2668129 G/A Missense NM_000719 Val Ile 1 0
CACNA1C chr12 2668205 C/G Missense NM_000719 Ala Gly 0 1
CDKL5 chrX 18526627 A/G Missense NM_001037343 His Arg 1 0
CDKL5 chrX 18581529 G/A Missense NM_001037343 Val Ile 0 1
EML1 chr14 99445547 A/G Missense NM_004434 Asn Ser 1 0
EML1 chr14 99450317 G/A Missense NM_004434 Asp Asn 1 0
FOXP2 chr7 114081280 C/A Missense NM_148899 Pro Thr 1 0
FOXP2 chr7 114091661 A/G Missense NM_148899 Asn Ser 1 0
FOXP2 chr7 114117153 A/C Missense NM_148899 His Pro 2 0
FOXP2 chr7 114117169 A/T Missense NM_148899 Glu Asp 1 0
GRID2 chr4 94563072 C/T Missense NM_001510 Pro Leu 1 0
GRID2 chr4 94766467 G/A Missense NM_001510 Val Ile 2 0
HOXA1 chr7 27101672 C/A Missense NM_005522 Ala Ser 0 1
HOXA1 chr7 27101822 T/C Missense NM_153620 Thr Ala 0 1
HOXA1 chr7 27101874 G/C Missense NM_153620 Ile Met 2 0
MAPK3 chr16 30035564 G/A Missense NM_002746 Pro Ser 1 0
MAPK3 chr16 30040668 T/G Missense NM_002746 Thr Pro 1 0
MECP2 chrX 152949868 G/C Missense NM_004992 Ala Gly 1 0
PTEN chr10 89680805 A/G Missense NM_000314 Thr Ala 1 0
PTEN chr10 89701980 C/G Missense NM_000314 Phe Leu 1 0
SHANK3 chr22 49490328 G/A Missense NM_001080420 Arg His 0 1
SHANK3 chr22 49506750 G/A Missense NM_001080420 Gly Asp 1 0
SHANK3 chr22 49506884 A/T Missense NM_001080420 Ser Cys 2 0
SHANK3 chr22 49507020 G/A Missense NM_001080420 Arg Lys 1 0
SHANK3 chr22 49507097 G/A Missense NM_001080420 Ala Thr 1 0
SHANK3 chr22 49507125 T/G Missense NM_001080420 Val Gly 0 1
SHANK3 chr22 49507260 C/T Missense NM_001080420 Thr Met 0 1
SHANK3 chr22 49507359 C/T Missense NM_001080420 Pro Lys 0 1
SHANK3 chr22 49507406 G/A Missense NM_001080420 Val Met 0 1
SHANK3 chr22 49516073 C/T Missense NM_001080420 Pro Ser 1 0
SHANK3 chr22 49516107 G/T Missense NM_001080420 Ser Ile 0 1
SHANK3 chr22 49516125 C/T Missense NM_001080420 Ala Val 2 0
SHANK3 chr22 49516230 C/T Missense NM_001080420 Thr Ile 1 0
SHANK3 chr22 49516308 G/A Missense NM_001080420 Arg His 1 0
SHANK3 chr22 49516325 C/T Missense NM_001080420 Pro Ser 1 0
SHANK3 chr22 49516329 C/T Missense NM_001080420 Ser Lys 1 0
SHANK3 chr22 49516346 G/A Missense NM_001080420 Arg Thr 1 0
SHANK3 chr22 49516365 G/A Missense NM_001080420 Gly Asp 3 0
SHANK3 chr22 49516370 C/A Missense NM_001080420 Pro Thr 1 1
SHANK3 chr22 49516374 G/A Missense NM_001080420 Gly Asp 0 1
TSC1 chr9 134761739 T/G Missense NM_000368 Met Leu 1 0
TSC1 chr9 134761835 C/T Missense NM_000368 Gly Ser 1 2
TSC1 chr9 134767919 T/C Missense NM_000368 Asn Ser 2 0
TSC1 chr9 134768873 G/A Missense NM_000368 His Tyr 2 3
TSC1 chr9 134771026 T/C Missense NM_000368 Lys Arg 7 1
TSC1 chr9 134771108 C/T Missense NM_000368 Gly Ser 0 1
TSC1 chr9 134772035 G/A Missense NM_000368 Pro Ser 1 0
TSC1 chr9 134775834 G/A Missense NM_000368 Ser Leu 2 0
Continued
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idiopathic autism (ASD of unknown etiology, with no
evident organic cause or underlying dysmorphisms). For the
latter, a genetic model in which several genes interact with
one another to produce the autism phenotype has been
suggested (6). Using family history studies and twin studies
of autism, Pickles et al.( 7) rejected single-locus and hetero-
geneity models for the inheritance of autism in favor of a
multi-locus model involving anything from 2 to 10 loci,
with three interacting loci being most plausible. However, to
date, there are no data to support or refute this model. In
this study, we set out to evaluate whether sequence variations
in genes known to cause syndromic autism contribute to the
etiology of high-functioning, non-syndromic autism.
RESULTS
We sequenced a total of 21 genes (ARX, ATRX, CACNA1C,
CDKL5, EML1, FMR1, FOXP2, GRID2, HOXA1, KCTD13,
MAPK3, MECP2, NLGN3, NLGN4X, PTEN, RS1, SHANK3,
SLC25A12, TSC1, TSC2 and UBE3A) known to cause syn-
dromic autism and other cognitive disorders (8–24), in
339 probands with high-functioning ASDs from the
Simons Simplex Collection. Sequencing was performed by
the traditional Sanger method, and coding non-synonymous
variants and coding insertions or deletions (indels) were con-
ﬁrmed by a second, independent sequencing method (454
pyrosequencing).
A total of 818 coding non-synonymous events were
detected at 92 sites, and 51 coding indels (11 sites) were ident-
iﬁed. Excluding all variants annotated in dbSNP131 and the
1000 Genomes Project (data release pilot 2) resulted in a
data set of 105 novel coding non-synonymous variants (66
sites) and 47 coding indels (8 sites) (Tables 1 and 2). Of
note, no nonsense mutations were detected in any of the 21
genes among the 339 probands tested, and only one frame-
shifting indel (HOXA1) that was inherited from a non-affected
parent was identiﬁed.
We were able to follow up on 115 variants of interest
(coding non-synonymous and coding indels), for which sufﬁ-
cient DNA from both parents was available. The analysis indi-
cated that whereas the vast majority of events (108/115) were
inherited from an unaffected parent, we did detect seven novel
coding non-synonymous variants (in six patients) that were de
novo events (Table 3). These de novo variants included three
different small indels and three different missense mutations.
All but one (a 3 bp deletion in HOXA1, present in two pro-
bands) were seen in single patients. One patient carried two
de novo variants in the HOXA1 gene, the aforementioned
small deletion, and a missense mutation in a moderately con-
served amino acid (p.I61M). One patient was found to carry a
de novo 9 bp deletion in TSC2, which was out of frame, there-
fore deleting four amino acids and inserting an arginine in a
highly conserved domain of the protein. Of note, this particu-
lar patient did not have a history of tuberous sclerosis, or a
positive family history of tuberous sclerosis. The Simons
Simplex Collection database does not contain information
Table 1. Continued
Gene name Chr Coordinate Allele Mutation type RefSeqID Ref AA Var AA Number affected
patients
Number affected
controls
TSC1 chr9 134776272 G/T Missense NM_000368 Thr Asn 3 1
TSC1 chr9 134776684 G/A Missense NM_000368 Arg Trp 1 0
TSC1 chr9 134776689 G/A Missense NM_000368 Ser Leu 0 1
TSC1 chr9 134790812 A/C Missense NM_000368 Leu Val 0 1
TSC2 chr16 2038634 G/A Missense NM_021056 Ser Asn 0 1
TSC2 chr16 2040411 A/G Missense NM_021056 Met Val 1 7
TSC2 chr16 2040453 A/G Missense NM_021056 Ile Val 0 0
TSC2 chr16 2043393 A/T Missense NM_021056 Glu Val 0 1
TSC2 chr16 2043407 G/A Missense NM_021056 Ala Thr 0 1
TSC2 chr16 2052990 G/A Missense NM_021056 Ala Thr 2 1
TSC2 chr16 2054427 A/C Missense NM_021056 Lys Gln 1 0
TSC2 chr16 2055530 C/T Missense NM_021056 Arg Cys 1 0
TSC2 chr16 2060557 A/G Missense NM_021056 Ile Val 1 0
TSC2 chr16 2061577 T/G Missense NM_021056 Asp Glu 0 1
TSC2 chr16 2061871 G/A Missense NM_021056 Ala Thr 2 0
TSC2 chr16 2066142 C/G Missense NM_021056 Phe Leu 1 1
TSC2 chr16 2067712 G/C Missense NM_000548 Glu Gln 1 2
TSC2 chr16 2069567 C/T Missense NM_021056 Pro Leu 1 0
TSC2 chr16 2070191 C/T Missense NM_021056 Ala Val 1 0
TSC2 chr16 2074318 C/T Missense NM_021056 Ser Leu 0 1
TSC2 chr16 2074330 G/A Missense NM_021056 Arg Gln 1 0
TSC2 chr16 2074497 G/A Missense NM_021056 Gly Arg 1 0
TSC2 chr16 2078075 C/A Missense NM_021056 Ser Arg 1 0
UBE3A chr15 23166916 T/A Missense NM_000462 Ser Cys 0 6
UBE3A chr15 23167822 C/T Missense NM_000462 Ala Thr 10 13
UBE3A chr15 23167903 T/C Missense NM_000462 Thr Ala 1 0
UBE3A chr15 23171810 T/G Missense NM_000462 Lys Gln 0 9
Coordinates based on genome build hg18. Chr, chromosome; AA, amino acid.
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this patient has a history of seizures. Another patient carried
a de novo missense mutation in PTEN, altering a moderately
conserved threonine to an alanine (p.T78A). The patient has
no known history or documented features of PTEN harmatoma
tumor syndrome and his head circumference was at the 25th
percentile. Lastly, two patients carried de novo mutations in
the FOXP2 gene. One had a missense variant of an amino
acid that is conserved throughout species (p.H603P) and
another patient had a 3 bp insertion, adding a glutamine in
yet another highly conserved domain of the protein (Fig. 1).
For all de novo mutations, unaffected siblings were tested, in
order to rule out the remote possibility of germline mosaicism.
None of the respective siblings carried the mutation identiﬁed
in the probands.
Aside from de novo mutations, we found an interesting
pattern of inheritance to the inherited events. Notably, 23/
339 probands (6.8%) were found to carry two or more
novel coding non-synonymous variants or coding indels in
the 21 genes analyzed, representing cases of oligogenic het-
erozygosity (Table 4). Follow up on these oligogenic var-
iants in the respective unaffected parents and siblings
revealed that only four of these combinations were present
in one of the parents, while 15 represented oligogenic com-
binations unique to the affected proband. Two additional
combinations could fall into the ‘unique’ category, as they
involve novel variants in the maternal allele of the UBE3A
gene. However, grandparental samples were not available
to further test the inheritance of the UBE3A allele. For
two oliogenic events, the inheritance pattern could not be
established, given failure of ampliﬁcation in at least one of
the two parents. Studying the unaffected siblings of 23 pro-
bands with oligogenic events, only 2 siblings were carriers
of the same oligogenic combination, while 15 did not
carry the respective combination. Ampliﬁcation failed in
two siblings and four probands did not have a sibling
enrolled in the study.
Eighteen of the 23 oligogenic events clustered among
7 genes (CACNA1C, CDKL5, HOXA1, SHANK3, TSC1,
TSC2 and UBE3A). We performed Sanger sequencing of the
entire coding regions of these 7 genes in a total of 376 con-
trols, the same methodology that was used in the autistic pro-
bands. Control individuals had undergone psychiatric
screening by questionnaire. Individuals with known psychia-
tric disorder or phenotypes consistent with obsessive-
compulsive behaviors were excluded from our study. While
a total of 99 coding non-synonymous variants and coding
indels were identiﬁed among controls in the 7 genes analyzed,
only 6 control individuals were carriers of oligogenic hetero-
zygous events of these genes. The incidence of oligogenic het-
erozygous variants in two or more of the seven genes is
signiﬁcantly different between probands (18/339, i.e. 5.31%)
and controls (6/376, i.e. 1.59%), as evidenced by Fisher’s
exact test (P , 0.01) (Table 5).
Retrospective analysis of the clinical phenotypes of pro-
bands affected with oligogenic compound heterozygosity
Table 2. Novel, coding Indels detected by Sanger sequencing of 21 autism susceptibility genes in 339 probands with the ASD
Gene name Chr Coordinate Mutation type Number of
basepairs
RefSeqID Reference
allele
Variant
allele
Number affected
patients
Number affected
controls
HOXA1 chr7 27101863 Deletion 3 NM_153620 TGG – 34 20
HOXA1 chr7 27101863 Insertion 3 NM_153620 – TGG 1 0
HOXA1 chr7 27101863 Insertion 6 NM_153620 – TGGTGG 1 0
HOXA1 chr7 27101863 Deletion 6 NM_153620 TGGTGG – 0 1
TSC1 chr9 134761828 Insertion 3 NM_000368 – CTG 0 1
UBE3A chr15 23167844 Deletion 6 NM_130839 CTTTTC – 1 0
HOXA1 chr7 27101857 Deletion 9 NM_153620 TGGTGGTGG – 1 0
TSC2 chr16 2072468 Deletion 9 NM_021056 GCTGCCAAG – 1 0
HOXA1 chr7 27100623 Frame shift deletion 1 NM_005522 C – 1 0
FOXP2 chr7 114058841 Insertion 3 NM_148899 – AGC 4 2
PTEN chr10 89680779 Exon boundary deletion 5 NM_000314 TTAGT – 1 0
Coordinates based on genome build hg18.
Table 3. De novo mutations detected by Sanger sequencing of 21 autism susceptibility genes in 339 probands with the ASD
Patient(s) Gene Chrom Coordinate Mutation type Reference allele Variant allele Reference amino acid Variant amino acid Conservation
11 598 FOXP2 7 114058841 Insertion – AGC – Gln 8/8 species
11 446 FOXP2 7 114117153 Missense A C His Pro 11/11 species
11 030 HOXA1 7 27101863 Deletion TGG – H – 6/9 species
11 452 HOXA1 7 27101863 Deletion TGG – H – 6/9 species
11 452 HOXA1 7 27101874 Missense G C Ile Met 5/7 species
11 532 PTEN 10 89680805 Missense A G Thr Ala 8/10 species
11 549 TSC2 16 2072468 Deletion GCTGCCAAG – Ser/Cys/Gln/Gly Arg 10/11 species
Based on genome build hg18. Conservation based on USCS Genome Browser.
Human Molecular Genetics, 2011, Vol. 20, No. 17 3369revealed that these individuals indeed represent a group of
high-functioning autism with a total average IQ of 93.05
(SD ¼ 22.75) (Table 6).
DISCUSSION
This study set out to identify the relationship of the genetics of
syndromic and non-syndromic autism. The fact that only 6/
339 probands (1.8%) carry a de novo novel, coding non-
synonymous variant or coding indel in the 21 genes examined
is consistent with their clinical presentation, as the patients
selected represented cases of idiopathic autism rather than syn-
dromic autism (which would be the expected phenotype
caused by loss-of-function mutations in most of the genes
tested). While this suggests that the individual mutations
causing syndromic versus non-syndromic autism may be sep-
arate from each other, the actual number of de novo missense
mutations in these genes is surprisingly high. It has been esti-
mated that on average, a newborn carries 0.86 de novo amino
acid altering mutations (25). Given this rate, our study of 21
genes in 339 probands should have revealed ,1 (0.27) de
novo missense mutations among these genes. The fact that
the actual number of de novo mutations is much higher
(22-fold increase for all tested genes) suggests that while
severe loss-of-function mutations of given genes may cause
syndromic autism, milder mutations of the same genes may
be associated with non-syndromic autism. However, the com-
parison of de novo mutation rates between our own cohort and
the per generation estimate cited above is limited by the fact
that they rely on different detection methods and statistical
analyses.
The two de novo mutations identiﬁed in TSC2 and PTEN are
clearly in genes known to cause syndromic autism. The other
four de novo variants were identiﬁed in HOXA1 and FOXP2,
genes that are yet to be conﬁrmed to be involved in autism or
thatshowphenotypesontheautismspectrum.Whileamissense
variant of HOXA1 was reported in association with autism (15),
mostsubsequentstudies hadfailed toreplicatean association of
the gene to autistic phenotypes (26–31). As part of this study,
we identiﬁed a de novo missense mutation of HOXA1 in one
patient, and a small de novo 3 bp deletion in a polyhistidine
tract of the protein in another. The latter was seen at relatively
high frequency (36 of 339 probands and 10 of 376 controls) and
likely represents a common variant.
Mutations in the forkhead-domain gene FOXP2 provided
evidence that the gene is critical for human speech and
language (14), but the number of autistic patients identiﬁed
with FOXP2 mutations has been very limited (32–35). In
this study, we identiﬁed two patients with de novo mutations
in FOXP2. While one of the two adds an additional glutamine
to a polyglutamine tract of the protein, which may represent a
Figure 1. De novo mutations and evolutionary conservation. Six de novo mutations detected by Sanger sequencing of 21 autism susceptibility genes in 339
probands from the Simons Simplex Collection. Reference amino acids are displayed in black, variant amino acids in the patients in red color. Amino acids
from different species which differ from the human sequence are displayed in green. Single line, no amino acids in the aligned species. Double line, aligned
species has no alignable amino acids in the respective region. Information based on UCSC Genome Browser human genome build 18.
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(p.H603P) in a protein domain that is highly conserved
throughout species. The two patients identiﬁed to carry de
novo mutations of FOXP2 were both diagnosed with AD.
Testing of their communication skills by the communication
domain of the Vineland Adaptive Behavioral Scale II
(VABS-II) revealed low scores in both individuals (74 in indi-
vidual 11 598, and 77 in individual 11 446), suggesting mod-
erate to signiﬁcant impairment of communicative skills in both
probands. These ﬁndings strengthen the role of FOXP2 and its
contributions to the ASDs.
Table 4. Parental and sibling data for all variants participating in oligogenic heterozygous events in 23 ASD probands
Patient Gene Chrom Coordinate Mutation type Patient status Mother status Father status Designated sib status
11 445 HOXA1 7 27101863 Indel (3 bp del) 1 1 0 0
11 445 TSC2 16 2061871 Missense G/A 1 1 0 1
11 450 CACNA1C 12 2668129 Missense G/A 1 0 1 1
11 450 SHANK3 22 49516308 Missense G/A 1 – 0 –
11 450 SHANK3 22 49516346 Missense G/A 1 – 0 –
11 184 HOXA1 7 27101863 Indel (3 bp del) 1 1 1 1
11 184 UBE3A 15 23167822 Missense C/T 1 1 0 1
11 542 HOXA1 7 27101863 Indel (3 bp del) 1 0 1 0
11 542 TSC1 9 134775834 Missense G/A 1 0 1 –
11 370 TSC1 9 134771026 Missense T/C 1 1 0 1
11 370 UBE3A 15 23167822 Missense C/T 1 0 1 0
11 590 CACNA1C 12 2437094 Missense C/T 1 1 0 0
11 590 TSC2 16 2067712 Missense G/C 1 0 1 1
11 049 CACNA1C 12 2658877 Missense G/A 1 1 0 0
11 049 CDKL5 X 18526627 Missense A/G 2 1 0 0
11 444 CACNA1C 12 2564912 Missense C/T 1 1 0 1
11 444 TSC1 9 134776272 Missense G/T 1 0 1 0
11 256 HOXA1 7 27101863 Indel (3 bp del) 1 1 0 1
11 256 TSC1 9 134776272 Missense G/T 1 0 1 1
11 402 HOXA1 7 27101860 Indel (6 bp del) 1 1 0 0
11 402 TSC2 16 2052990 Missense G/A 1 – – 0
11 540 TSC1 9 134776684 Missense G/A 1 0 1 0
11 540 TSC2 16 2070191 Missense C/T 1 0 1 1
11 540 TSC2 16 2078075 Missense C/A 1 1 0 1
11 028 CACNA1C 12 2665254 Missense C/T 1 1 0 0
11 028 FOXP2 7 114117153 Missense A/C 1 1 0 0
11 598 FOXP2 7 114058841 Indel (3 bp ins) 1 0 0 x
11 598 GRID2 4 94766467 Missense G/A 1 0 1 x
11 546 TSC1 9 134768873 Missense G/A 1 1 0 0
11 546 UBE3A 15 23167822 Missense C/T 1 0 1 0
11 468 HOXA1 7 27101863 Indel (3 bp del) 1 1 0 x
11 468 UBE3A 15 23167822 Missense C/T 1 1 0 x
11 376 TSC1 9 134771026 Missense T/C 1 1 0 1
11 376 GRID2 4 94766467 Missense G/A 1 0 1 0
11 202 CACNA1C 12 2665254 Missense C/T 1 1 0 x
11 202 TSC1 9 134771026 Missense T/C 1 2 0 x
11 202 EML1 14 99450317 Missense G/A 1 0 1 x
11 290 SHANK3 22 49516073 Missense C/T 2 – – –
11 290 TSC1 9 134771026 Missense T/C 1 0 1 1
11 685 CACNA1C 12 2658928 Missense G/A 1 0 1 0
11 685 MECP2 X 152949868 Missense G/C 2 1 0 0
11 714 HOXA1 7 27101863 Indel (3 bp del) 1 1 0 –
11 714 CACNA1C 12 2564900 Missense G/A 1 0 1 0
11 780 CACNA1C 12 2662090 Missense T/C 1 – 1 x
11 780 GRID2 4 94563072 Missense C/T 1 – 1 x
11 724 UBE3A 15 23167822 Missense C/T 1 1 0 0
11 724 SHANK3 22 49516370 Missense C/A 1 – – –
11 543 UBE3A 15 23167844 Indel (6 bp del) 1 0 1 0
11 543 TSC2 16 2054427 Missense A/C 1 1 0 1
‘0’,homozygous for referenceallele; ‘1’,heterozygous for variant allele; ‘2’,homozygous or hemizygous for variant allele; ‘–’, data not available; ‘x’,no sibiling.
Coordinates based on genome build hg18.
Table 5. Fisher’s exact test analysis for oligogenic heterozygous events
Observed Case Control Total
Oligogenic event 18 6 24
No oligogenic event 321 370 691
Total 339 376 715
Probands with high-functioning ASD and control individuals display
signiﬁcantly different frequencies of oligogenic heterozygous events in two or
more of seven genes (P ¼ 0.00653, Fisher’s exact test).
Human Molecular Genetics, 2011, Vol. 20, No. 17 3371As part of this study, 18 of 339 probands were found to be
carriers of novel oligogenic heterozygous coding variants,
even among the small number of genes analyzed. The occur-
rence of oligogenic heterozygous events is of particular inter-
est, as it has been suggested before that autism could represent
a complex genetic disorder that results from simultaneous
genetic variations in multiple genes (4). Following the same
concept, a two-hit model for CNVs has been proposed for
severe developmental delay (36) and subsequently been dis-
cussed for epilepsy as well (37). For autism, Pinto et al. (38)
reported the occasional combination of de novo and inherited
CNVs within a given family. While this study of 21 genes pro-
vides limited insight in the actual complexity of autism gen-
etics, the data show signiﬁcant increase in oliogogenic
heterozygous combinations of novel coding variants in genes
such as CACNA1C, CDKL5, HOXA1, SHANK3, TSC1, TSC2
and UBE3A among autistic probands compared with control
individuals. Given the uncertain signiﬁcance of the aforemen-
tioned 3 bp deletion in the polyhistidine tract of HOXA1, we
re-analyzed our data set excluding this common variant.
This would leave 14 oligogenic heterozygous events among
339 probands and 4 oligogenic heterozygous events among
376 controls, which is still highly signiﬁcant by Fisher’s
exact test (P ¼ 0.01448).
Studying the parents and unaffected siblings for the pres-
ence of oligogenic events revealed that the vast majority of
these combinations are unique to the proband. However, the
fact that four parents and two siblings carried the same com-
binations of oligogenic heterozygosity reveals that at least
some of these events on their own are not sufﬁcient to cause
autism. One might speculate that the accumulation of
several, if not many of such hypomorphic mutations causes
a genetic load, which will ultimately cross a given threshold
and lead to clinical manifestation of the ASD in the respective
individuals (Fig. 2). Our study is limited by the small number
of genes tested, and the full range of oligogenic heterozygous
events contributing to the etiology of autism will only become
evident once large scale, whole exome or whole genome data
sets of sequences from autistic individuals are analyzed to
evaluate for such combinatorial events. Also, while our
study detected a signiﬁcant difference in the incidence of oli-
gogenic heterozygous variants between probands and controls
for the aforementioned genes, it might be the case that controls
have different heterozygous combinations with other genes
that were not tested.
‘Synergistic heterozygosity’ has been described as a poten-
tial disease mechanism in some metabolic disorders, with the
idea that concurrent partial defects in more than one pathway,
or at multiple steps in one pathway may lead to disease, even
though no complete deﬁciency in any one enzyme is present
(39). In the ﬁeld of autism genetics, several hypomorphic var-
iants may accumulate either in a speciﬁc signaling pathway, or
a subcellular compartment (such as the synapse) to exceed a
threshold and result in phenotypic manifestation. This would
be consistent with the data from clinical studies whereby chil-
dren from families in which both parents manifest sub-
threshold autistic traits are more likely to show more severe
impairment in reciprocal and social behavior (40).
It is noteworthy that the average full-scale IQ of individuals
with de novo mutations in some of the 21 autism susceptibility
genes was 71.6 (SD ¼ 19.2), whereas the average full-scale IQ
of those with oligogenic heterozygous events without de novo
mutations was 94.1 (SD ¼ 22.2). While evidence is emerging
that intellectual disabilities might be widely attributable to de
Table 6. Clinical phenotypes and the genes involved in oligogenic heterozygous events among 23 probands with ASD
Patient ID Sex Age (years) Diagnosis IQ score (total) First gene Second gene
11 445 Male 8 AD 78 HOXA1 TSC2
11 450 Male 5 PDD-NOS 77 CACNA1C SHANK3
11 184 Male 9 AD 93 HOXA1 UBE3A
11 542 Female 12 PDD-NOS 116 HOXA1 TSC1
11 370 Male 14 AD 96 TSC1 UBE3A
11 590 Male 10 Asperger 96 CACNA1C TSC2
11 049 Male 7 PDD-NOS 137 CACNA1C CDKL5
11 444 Female 16 Asperger 104 CACNA1C TSC1
11 256 Male 11 AD 108 HOXA1 TSC1
11 402 Male 8 PDD-NOS 91 HOXA1 TSC2
11 540 Male 8 PDD-NOS 57 TSC1 TSC2
11 028 Male 9 AD 108 CACNA1C FOXP2
11 598 Male 5 AD 71 FOXP2 GRID2
11 546 Male 11 Asperger 119 TSC1 UBE3A
11 468 Male 10 PDD-NOS 87 HOXA1 UBE3A
11 376 Male 7 AD 91 TSC1 GRID2
11 202 Male 11 PDD-NOS 82 CACNA1C TSC1
11 290 Male 11 AD 131 SHANK3 TSC1
11 685 Male 5 AD 98 CACNA1C MECP2
11 714 Male 6 Asperger 95 CACNA1C HOXA1
11 724 Male 10 AD 55 SHANK3 UBE3A
11 543 Male 16 AD 57 TSC2 UBE3A
Average 9.5 93.05
SD 3.19 22.75
AD, autistic disorder; PDD-NOS, pervasive developmental disorder not otherwise speciﬁed.
3372 Human Molecular Genetics, 2011, Vol. 20, No. 17novo mutations (41), cases of the high-functioning ASD may
rather be attributable to co-inheritance of subtle, yet function-
ally signiﬁcant variants in respective genes.
In summary, our data uncovered de novo mutations in 1.8%
of the ASD patients we studied and suggest that oligogenic
heterozygosity of coding non-synonymous variants and
coding indels may constitute a novel pathogenic mechanism
or risk for ASDs. The data from this study provide a frame-
work upon which to expand investigations into oligogenic
events in larger data sets. A model of oligogenic heterozygos-
ity may offer at least a partial explanation for why traditional
linkage analysis and mapping approaches have been rather
unsuccessful in identifying genetic variants predisposing to
ASDs. Whole exome sequencing analyzed in the context of
genes involved in pathways critical for neuronal development
and function is likely to be a productive approach to unravel
oligogenic and combinatorial events that might increase an
individual’s risk for ASDs.
MATERIALS AND METHODS
Subject recruitment
We obtained DNA samples (from lymphoblast cell lines) from
probands and their family members through the Simons
Simplex Collection (SSC), a resource of the Simons Foun-
dation Autism Research Initiative (SFARI). The SSC rep-
resents a repository of clinical, neuropsychological,
phenotypic and genetic data of .2000 families with simplex
autism. This is a collection of cases of sporadic (‘simplex’)
autism with unaffected parents and unaffected siblings. On
average, probands in the SSC exhibit moderate-to-severe
autistic symptoms with relatively little intellectual disability
(42). Control DNAs were obtained from the NIMH through
the Center for Collaborative Genetic Studies on Mental Dis-
orders. Control individuals had undergone a comprehensive
online psychiatric questionnaire.
Controls were ruled out if they
† Replied 1 (Yes) to both A8d and A8e (Depression);
† Replied 1 (Yes) to both B14 and B15 (Generalized
Anxiety Disorder);
† Replied 3, 4 or 5 to G2a or replied 5 to G7a (Alcohol
Dependence);
† Replied 1 to H3 AND 3, 4 or 5 to H3a (Drug Depen-
dence);
† Replied 1 or 21 to any question of section I (Obsessive
Compulsive Behavior).
Probands and controls were sex matched at a ratio of M:F ¼
6.8:1.
Sequencing
We have designed primers and ampliﬁed coding regions and
intron/exon junctions of the 21 genes according to standard
protocols. polymerase chain reaction (PCR) products were
sequenced using traditional Sanger ﬂuorescent di-deoxy
methods on ABI 3730 capillary sequencers. Resulting
sequences were analyzed and single nucleotide variants and
Indels detected using SNPdetector software (43).
Validation
All coding non-synonymous variants and coding indels
detected in Sanger sequencing were assayed with
PCR-directed orthogonal sequencing validation. Targets
were re-ampliﬁed, and resulting PCR reactions pooled and
sequenced using 454 pyrosequencing. Resulting 454 reads
were mapped to the human reference sequence using BLAT
and CrossMatch alignment software. We required coverage
Figure 2. Proposed models of inheritance for ASDs. Left panel: syndromic autism is mostly caused by severe loss-of-function mutations of speciﬁc genes, with
each gene causing a speciﬁc syndrome. Right panel: non-syndromic autism may be caused by milder mutations in genes that are known to cause syndromic
autism or by mutations in novel genes, unrelated to syndromic autism. Oligogenic heterozygosity of hypomorphic variants in genes known to cause syndromic
autism may have a cumulative effect, resulting in non-syndromic autism. Mutations may be point mutations or coding indels, as well as CNVs.
Human Molecular Genetics, 2011, Vol. 20, No. 17 3373of .50 at the site and variant allele fraction .20% to validate
a variant.
ACKNOWLEDGMENTS
We thank Arthur L. Beaudet for helpful discussions and col-
laboration; Christie Kovar, Irene Newsham and Yuan-Qing
Wu for technical assistance; Robin Kochel and Kerri Nowell
for their help screening the SSC databases; and Alanna
McCall for data management. We are grateful to all of the
families at the participating SFARI Simplex Collection
(SSC) sites, as well as the principal investigators (A.
Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne,
D. Geschwind, R. Goin-Kochel, D. Grice, A. Klin, D.
Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim,
J. Miles, O. Ousley, B. Peterson, J. Piggot, C. Saulnier,
M. State,W. Stone, J. Sutcliffe, C. Walsh, E. Wijsman).
Conﬂict of Interest statement. None declared.
FUNDING
This work was supported by a grant from the Simons Foun-
dation (SFARI 128234 to H.Y.Z. and R.A.G.). H.Y.Z. and
Y.S. are supported by the Howard Hughes Medical Institute.
Funding to pay the Open Access publication charges for this
article was provided by HHMI.
REFERENCES
1. Kogan, M.D., Blumberg, S.J., Schieve, L.A., Boyle, C.A., Perrin, J.M.,
Ghandour, R.M., Singh, G.K., Strickland, B.B., Trevathan, E. and van
Dyck, P.C. (2009) Prevalence of parent-reported diagnosis of autism
spectrum disorder among children in the US, 2007. Pediatrics, 124,
1395–1403.
2. (2009) Prevalence of autism spectrum disorders - Autism and
Developmental Disabilities Monitoring Network, United States, 2006.
MMWR Surveill. Summ., 58, 1–20.
3. Gillberg, C. and Ehlers, S. (1998) High-functioning people with autism
and asperger syndrome: a literature review. In Schopler, E., Mesibov,
G.B. and Kunce, L.J. (eds), Asperger Syndrome or High-Functioning
Autism? Plenum Press, New York, pp. 79–106.
4. El-Fishawy, P. and State, M.W. (2010) The genetics of autism: key issues,
recent ﬁndings, and clinical implications. Psychiatr. Clin. North. Am., 33,
83–105.
5. Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C., Walsh, T.,
Yamrom, B., Yoon, S., Krasnitz, A., Kendall, J. et al. (2007) Strong
association of de novo copy number mutations with autism. Science, 316,
445–449.
6. Folstein, S.E. and Rosen-Sheidley, B. (2001) Genetics of autism: complex
aetiology for a heterogeneous disorder. Nat. Rev. Genet., 2, 943–955.
7. Pickles, A., Bolton, P., Macdonald, H., Bailey, A., Le Couteur, A., Sim,
C.H. and Rutter, M. (1995) Latent-class analysis of recurrence risks for
complex phenotypes with selection and measurement error: a twin and
family history study of autism. Am. J. Hum. Genet., 57, 717–726.
8. Sherr, E.H. (2003) The ARX story (epilepsy, mental retardation, autism,
and cerebral malformations): one gene leads to many phenotypes. Curr.
Opin. Pediatr., 15, 567–571.
9. Gong, X., Bacchelli, E., Blasi, F., Toma, C., Betancur, C., Chaste, P.,
Delorme, R., Durand, C.M., Fauchereau, F., Botros, H.G. et al. (2008)
Analysis of X chromosome inactivation in autism spectrum disorders.
Am. J. Med. Genet. B Neuropsychiatr. Genet., 147B, 830–835.
10. Splawski, I., Yoo, D.S., Stotz, S.C., Cherry, A., Clapham, D.E. and
Keating, M.T. (2006) CACNA1H mutations in autism spectrum disorders.
J. Biol. Chem., 281, 22085–22091.
11. Weaving, L.S., Christodoulou, J., Williamson, S.L., Friend, K.L.,
McKenzie, O.L., Archer, H., Evans, J., Clarke, A., Pelka, G.J., Tam, P.P.
et al. (2004) Mutations of CDKL5 cause a severe neurodevelopmental
disorder with infantile spasms and mental retardation. Am. J. Hum. Genet.,
75, 1079–1093.
12. Eudy, J.D., Ma-Edmonds, M., Yao, S.F., Talmadge, C.B., Kelley, P.M.,
Weston, M.D., Kimberling, W.J. and Sumegi, J. (1997) Isolation of a
novel human homologue of the gene coding for echinoderm
microtubule-associated protein (EMAP) from the Usher syndrome type 1a
locus at 14q32. Genomics, 43, 104–106.
13. Hatton, D.D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D.B. Jr,
Roberts, J. and Mirrett, P. (2006) Autistic behavior in children with fragile
X syndrome: prevalence, stability, and the impact of FMRP. Am. J. Med.
Genet. A, 140A, 1804–1813.
14. Lai, C.S., Fisher, S.E., Hurst, J.A., Vargha-Khadem, F. and Monaco, A.P.
(2001) A forkhead-domain gene is mutated in a severe speech and
language disorder. Nature, 413, 519–523.
15. Ingram, J.L., Stodgell, C.J., Hyman, S.L., Figlewicz, D.A., Weitkamp,
L.R. and Rodier, P.M. (2000) Discovery of allelic variants of HOXA1 and
HOXB1: genetic susceptibility to autism spectrum disorders. Teratology,
62, 393–405.
16. Lasalle, J.M. and Yasui, D.H. (2009) Evolving role of MeCP2 in Rett
syndrome and autism. Epigenomics, 1, 119–130.
17. Jamain, S., Quach, H., Betancur, C., Rastam, M., Colineaux, C., Gillberg,
I.C., Soderstrom, H., Giros, B., Leboyer, M., Gillberg, C. et al. (2003)
Mutations of the X-linked genes encoding neuroligins NLGN3 and
NLGN4 are associated with autism. Nat. Genet., 34, 27–29.
18. Laumonnier, F., Bonnet-Brilhault, F., Gomot, M., Blanc, R., David, A.,
Moizard, M.P., Raynaud, M., Ronce, N., Lemonnier, E., Calvas, P. et al.
(2004) X-linked mental retardation and autism are associated with a
mutation in the NLGN4 gene, a member of the neuroligin family.
Am. J. Hum. Genet., 74, 552–557.
19. Butler, M.G., Dasouki, M.J., Zhou, X.P., Talebizadeh, Z., Brown, M.,
Takahashi, T.N., Miles, J.H., Wang, C.H., Stratton, R., Pilarski, R. et al.
(2005) Subset of individuals with autism spectrum disorders and extreme
macrocephaly associated with germline PTEN tumour suppressor gene
mutations. J. Med. Genet., 42, 318–321.
20. Durand, C.M., Betancur, C., Boeckers, T.M., Bockmann, J., Chaste, P.,
Fauchereau, F., Nygren, G., Rastam, M., Gillberg, I.C., Anckarsater, H.
et al. (2007) Mutations in the gene encoding the synaptic scaffolding
protein SHANK3 are associated with autism spectrum disorders. Nat.
Genet., 39, 25–27.
21. Ramoz, N., Reichert, J.G., Smith, C.J., Silverman, J.M., Bespalova, I.N.,
Davis, K.L. and Buxbaum, J.D. (2004) Linkage and association of the
mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism.
Am. J. Psychiatry, 161, 662–669.
22. Tavazoie, S.F., Alvarez, V.A., Ridenour, D.A., Kwiatkowski, D.J. and
Sabatini, B.L. (2005) Regulation of neuronal morphology and function by
the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci., 8, 1727–1734.
23. Serajee, F.J., Nabi, R., Zhong, H. and Mahbubul Huq, A.H. (2003)
Association of INPP1, PIK3CG, and TSC2 gene variants with autistic
disorder: implications for phosphatidylinositol signalling in autism.
J. Med. Genet., 40, e119.
24. Glessner, J.T., Wang, K., Cai, G., Korvatska, O., Kim, C.E., Wood, S.,
Zhang, H., Estes, A., Brune, C.W., Bradﬁeld, J.P. et al. (2009) Autism
genome-wide copy number variation reveals ubiquitin and neuronal
genes. Nature, 459, 569–573.
25. Lynch, M. (2010) Rate, molecular spectrum, and consequences of human
mutation. Proc. Natl Acad. Sci. USA, 107, 961–968.
26. Li, J., Tabor, H.K., Nguyen, L., Gleason, C., Lotspeich, L.J., Spiker, D.,
Risch, N. and Myers, R.M. (2002) Lack of association between HoxA1
and HoxB1 gene variants and autism in 110 multiplex families.
Am. J. Med. Genet., 114, 24–30.
27. Devlin, B., Bennett, P., Cook, E.H. Jr, Dawson, G., Gonen, D.,
Grigorenko, E.L., McMahon, W., Pauls, D., Smith, M., Spence, M.A.
et al. (2002) No evidence for linkage of liability to autism to HOXA1 in a
sample from the CPEA network. Am. J. Med. Genet., 114, 667–672.
28. Talebizadeh, Z., Bittel, D.C., Miles, J.H., Takahashi, N., Wang, C.H.,
Kibiryeva, N. and Butler, M.G. (2002) No association between HOXA1
and HOXB1 genes and autism spectrum disorders (ASD). J. Med. Genet.,
39, e70.
29. Romano, V., Cali, F., Mirisola, M., Gambino, G., D’Anna, R., Di Rosa, P.,
Seidita, G., Chiavetta, V., Aiello, F., Canziani, F. et al. (2003) Lack of
3374 Human Molecular Genetics, 2011, Vol. 20, No. 17association of HOXA1 and HOXB1 mutations and autism in Sicilian
(Italian) patients. Mol. Psychiatry, 8, 716–717.
30. Collins, J.S., Schroer, R.J., Bird, J. and Michaelis, R.C. (2003) The
HOXA1 A218G polymorphism and autism: lack of association in white
and black patients from the South Carolina Autism Project. J. Autism Dev.
Disord., 33, 343–348.
31. Gallagher, L., Hawi, Z., Kearney, G., Fitzgerald, M. and Gill, M. (2004)
No association between allelic variants of HOXA1/HOXB1 and autism.
Am. J. Med. Genet. B Neuropsychiatr. Genet., 124B, 64–67.
32. Newbury, D.F., Bonora, E., Lamb, J.A., Fisher, S.E., Lai, C.S., Baird, G.,
Jannoun, L., Slonims, V., Stott, C.M., Merricks, M.J. et al. (2002) FOXP2
is not a major susceptibility gene for autism or speciﬁc language
impairment. Am. J. Hum. Genet., 70, 1318–1327.
33. Wassink, T.H., Piven, J., Vieland, V.J., Pietila, J., Goedken, R.J., Folstein,
S.E. and Shefﬁeld, V.C. (2002) Evaluation of FOXP2 as an autism
susceptibility gene. Am. J. Med. Genet., 114, 566–569.
34. Gauthier, J., Joober, R., Mottron, L., Laurent, S., Fuchs, M., De Kimpe, V.
and Rouleau, G.A. (2003) Mutation screening of FOXP2 in individuals
diagnosed with autistic disorder. Am. J. Med. Genet. A, 118A, 172–175.
35. MacDermot, K.D., Bonora, E., Sykes, N., Coupe, A.M., Lai, C.S., Vernes,
S.C., Vargha-Khadem, F., McKenzie, F., Smith, R.L., Monaco, A.P. et al.
(2005) Identiﬁcation of FOXP2 truncation as a novel cause of
developmental speech and language deﬁcits. Am. J. Hum. Genet., 76,
1074–1080.
36. Girirajan, S., Rosenfeld, J.A., Cooper, G.M., Antonacci, F., Siswara, P.,
Itsara, A., Vives, L., Walsh, T., McCarthy, S.E., Baker, C. et al. (2010) A
recurrent 16p12.1 microdeletion supports a two-hit model for severe
developmental delay. Nat. Genet., 42, 203–209.
37. Mulley, J.C. and Mefford, H.C. (2011) Epilepsy and the new cytogenetics.
Epilepsia, 52, 423–432.
38. Pinto, D., Pagnamenta, A.T., Klei, L., Anney, R., Merico, D., Regan, R.,
Conroy, J., Magalhaes, T.R., Correia, C., Abrahams, B.S. et al. (2010)
Functional impact of global rare copy number variation in autism
spectrum disorders. Nature, 466, 368–372.
39. Vockley, J., Rinaldo, P., Bennett, M.J., Matern, D. and Vladutiu, G.D.
(2000) Synergistic heterozygosity: disease resulting from multiple
partial defects in one or more metabolic pathways. Mol. Genet. Metab., 71,
10–18.
40. Constantino, J.N. and Todd, R.D. (2005) Intergenerational transmission of
subthreshold autistic traits in the general population. Biol. Psychiatry, 57,
655–660.
41. Vissers, L.E., de Ligt, J., Gilissen, C., Janssen, I., Steehouwer, M., de
Vries, P., van Lier, B., Arts, P., Wieskamp, N., del Rosario, M. et al.
(2010) A de novo paradigm for mental retardation. Nat. Genet., 42,
1109–1112.
42. Fischbach, G.D. and Lord, C. (2010) The Simons Simplex Collection:
a resource for identiﬁcation of autism genetic risk factors. Neuron, 68,
192–195.
43. Zhang, J., Wheeler, D.A., Yakub, I., Wei, S., Sood, R., Rowe, W., Liu,
P.P., Gibbs, R.A. and Buetow, K.H. (2005) SNPdetector: a software
tool for sensitive and accurate SNP detection. PLoS Comput.
Biol., 1, e53.
Human Molecular Genetics, 2011, Vol. 20, No. 17 3375